Multiple Sclerosis-associated Bacterial Ligand 654

Doshi, 2016, Multiple sclerosis, a treatable disease, Clin Med (Lond), 16, s53, 10.7861/clinmedicine.16-6-s53 Sospedra, 2005, Immunology of multiple sclerosis, Annu Rev Immunol, 23, 683, 10.1146/annurev.immunol.23.021704.115707 Wang, 2018, The Properties of Cytokines in Multiple Sclerosis: Pros and Cons, Am J Med Sci, 356, 552, 10.1016/j.amjms.2018.08.018 Yamasaki, 2014, Differential roles of microglia and monocytes in the inflamed central nervous system, J Exp Med, 211, 1533, 10.1084/jem.20132477 Guerrero, 2020, Microglia in Multiple Sclerosis: Friend or Foe?, Front Immunol, 11, 374, 10.3389/fimmu.2020.00374 Walker, 2015, Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains, Alzheimers Res Ther, 7, 56, 10.1186/s13195-015-0139-9 Zia, 2020, Microglia Diversity in Health and Multiple Sclerosis, Front Immunol, 11, 10.3389/fimmu.2020.588021 Chu, 2018, The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis, J Neuroimmunol, 318, 1, 10.1016/j.jneuroim.2018.02.015 Rutsch, 2020, The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology, Front Immunol, 11, 10.3389/fimmu.2020.604179 Chen, 2016, Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls, Sci Rep, 6, 28484, 10.1038/srep28484 Jangi, 2016, Alterations of the human gut microbiome in multiple sclerosis, Nat Commun, 7, 12015, 10.1038/ncomms12015 Cekanaviciute, 2017, Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models, Proc Natl Acad Sci USA, 114, 10713, 10.1073/pnas.1711235114 Clark, 2013, Serine lipids of Porphyromonas gingivalis are human and mouse Toll-like receptor 2 ligands, Infect Immun, 81, 3479, 10.1128/IAI.00803-13 Farrokhi, 2013, Bacterial lipodipeptide, Lipid 654, is a microbiome-associated biomarker for multiple sclerosis, Clin Transl Immunology, 2, e8, 10.1038/cti.2013.11 Klotz, 2019, Risks and risk management in modern multiple sclerosis immunotherapeutic treatment, Ther Adv Neurol Disord, 12, 10.1177/1756286419836571 Miranda-Hernandez, 2013, Role of toll-like receptors in multiple sclerosis, Am J Clin Exp Immunol, 2, 75 Trivedi, 2009, Endosomal Toll-like receptors in autoimmunity: mechanisms for clinical diversity, Therapy, 6, 433, 10.2217/thy.09.2 Brinkmann, 2010, Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis, Nat Rev Drug Discov, 9, 883, 10.1038/nrd3248 Chaudhry, 2017, Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis, Neurotherapeutics, 14, 859, 10.1007/s13311-017-0565-4 Salvi, 2017, Role of Atypical Chemokine Receptors in Microglial Activation and Polarization, Front Aging Neurosci, 9, 148, 10.3389/fnagi.2017.00148 Ka, 2014, Phenotypic diversity and emerging new tools to study macrophage activation in bacterial infectious diseases, Front Immunol, 5, 500, 10.3389/fimmu.2014.00500 Dickinson B. Multicolor Flow Cytometry: Principles of Panel Design, Stain Index. 2004. Du, 2017, Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target, Mol Neurobiol, 54, 7567, 10.1007/s12035-016-0245-0 Simpson, 1998, Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions, J Neuroimmunol, 84, 238, 10.1016/S0165-5728(97)00208-7 Cheng, 2014, Chemokines and chemokine receptors in multiple sclerosis, Mediators Inflamm, 2014, 10.1155/2014/659206 Muls, 2017, IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy, PLoS One, 12, 10.1371/journal.pone.0173780 Wasko, 2020, Multiple sclerosis, the microbiome, TLR2, and the hygiene hypothesis, Autoimmun Rev, 19, 10.1016/j.autrev.2019.102430 Orihuela, 2016, Microglial M1/M2 polarization and metabolic states, Br J Pharmacol, 173, 649, 10.1111/bph.13139 Rossi, 2011, Potential role of IL-13 in neuroprotection and cortical excitability regulation in multiple sclerosis, Mult Scler, 17, 1301, 10.1177/1352458511410342 Jaguin, 2013, Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin, Cell Immunol, 281, 51, 10.1016/j.cellimm.2013.01.010 Broux, 2012, CX(3)CR1 drives cytotoxic CD4(+)CD28(–) T cells into the brain of multiple sclerosis patients, J Autoimmun, 38, 10, 10.1016/j.jaut.2011.11.006 Mattison, 2013, Suppressed pro-inflammatory response of microglia in CX3CR1 knockout mice, J Neuroimmunol, 257, 110, 10.1016/j.jneuroim.2013.02.008 Taylor, 2015, Microglial CX3CR1 is required for M2 polarization after intracerebral hemorrhage (INC1P.350), J Immunol, 194, 54 Ishida, 2017, Essential involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced pulmonary fibrosis via regulation of fibrocyte and M2 macrophage migration, Sci Rep, 7, 16833, 10.1038/s41598-017-17007-8 Burgess, 2019, Cx3CR1 Expression Identifies Distinct Macrophage Populations That Contribute Differentially to Inflammation and Repair, Immunohorizons, 3, 262, 10.4049/immunohorizons.1900038